Abbott Laboratories (NYSE:ABT) Price Target Cut to $135.00 by Analysts at Royal Bank Of Canada

Abbott Laboratories (NYSE:ABT) had its price objective reduced by analysts at Royal Bank Of Canada from $147.00 to $135.00 in a report issued on Friday,Benzinga reports. The firm currently has an “outperform” rating on the healthcare product maker’s stock. Royal Bank Of Canada’s price target suggests a potential upside of 24.21% from the stock’s previous close.

Several other equities analysts have also recently weighed in on the company. Raymond James Financial decreased their price objective on Abbott Laboratories from $146.00 to $130.00 and set an “outperform” rating for the company in a report on Friday. Jefferies Financial Group increased their price target on shares of Abbott Laboratories from $145.00 to $149.00 and gave the company a “buy” rating in a research note on Thursday, October 16th. Weiss Ratings reissued a “buy (b-)” rating on shares of Abbott Laboratories in a research report on Monday, December 29th. William Blair raised Abbott Laboratories to a “strong-buy” rating in a research report on Thursday, November 20th. Finally, Wells Fargo & Company lifted their target price on Abbott Laboratories from $142.00 to $146.00 and gave the stock an “overweight” rating in a research note on Thursday, October 16th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, Abbott Laboratories currently has a consensus rating of “Moderate Buy” and an average target price of $143.37.

Abbott Laboratories Trading Up 0.1%

Shares of ABT traded up $0.08 during trading hours on Friday, reaching $108.69. The stock had a trading volume of 2,307,181 shares, compared to its average volume of 8,972,974. Abbott Laboratories has a 52 week low of $105.78 and a 52 week high of $141.23. The company has a quick ratio of 1.24, a current ratio of 1.70 and a debt-to-equity ratio of 0.23. The company has a market cap of $189.00 billion, a P/E ratio of 13.65, a P/E/G ratio of 2.00 and a beta of 0.72. The firm has a 50-day moving average of $125.23 and a 200 day moving average of $128.54.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share for the quarter, hitting the consensus estimate of $1.50. Abbott Laboratories had a return on equity of 17.60% and a net margin of 31.88%.The company had revenue of $11.46 billion during the quarter, compared to analysts’ expectations of $11.80 billion. During the same period in the prior year, the firm earned $1.34 earnings per share. Abbott Laboratories’s revenue for the quarter was up 4.4% compared to the same quarter last year. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, sell-side analysts expect that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Abbott Laboratories

Institutional investors and hedge funds have recently made changes to their positions in the business. TCV Trust & Wealth Management Inc. boosted its holdings in shares of Abbott Laboratories by 3.9% during the 4th quarter. TCV Trust & Wealth Management Inc. now owns 123,773 shares of the healthcare product maker’s stock valued at $15,508,000 after purchasing an additional 4,649 shares during the last quarter. Fortune Financial Advisors LLC increased its stake in Abbott Laboratories by 2.5% in the 4th quarter. Fortune Financial Advisors LLC now owns 12,406 shares of the healthcare product maker’s stock worth $1,554,000 after acquiring an additional 302 shares during the last quarter. Brown Lisle Cummings Inc. boosted its position in shares of Abbott Laboratories by 14.6% during the 4th quarter. Brown Lisle Cummings Inc. now owns 4,706 shares of the healthcare product maker’s stock valued at $590,000 after acquiring an additional 600 shares during the last quarter. Capital Planning LLC increased its position in Abbott Laboratories by 135.1% in the fourth quarter. Capital Planning LLC now owns 18,758 shares of the healthcare product maker’s stock worth $2,330,000 after purchasing an additional 10,780 shares during the last quarter. Finally, Aljian Capital Management LLC raised its stake in Abbott Laboratories by 4.7% during the fourth quarter. Aljian Capital Management LLC now owns 5,127 shares of the healthcare product maker’s stock valued at $642,000 after purchasing an additional 230 shares in the last quarter. Hedge funds and other institutional investors own 75.18% of the company’s stock.

More Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Several sell‑side analysts kept constructive ratings and still see meaningful upside — Piper Sandler cut its price target to $135 but remains “overweight,” and BTIG trimmed its target to $140 while keeping a “buy” call, signaling continued analyst confidence despite the pullback. Benzinga
• Positive Sentiment: Med tech (devices) and Established Pharmaceuticals delivered strong growth (double‑digit devices, mid‑single to high single pharma), which management says helped offset weakness in other segments and supports the company’s multi‑year growth thesis. Blockonomi
• Positive Sentiment: Market commentators view the pullback as a potential buying opportunity for long‑term investors because Abbott remains a cash‑generative Dividend King with capacity for buybacks and continued margin improvement. MarketBeat
• Neutral Sentiment: Adjusted EPS of $1.50 matched consensus, showing underlying earnings resilience even as revenues lagged; GAAP results included items that lowered headline net income. Press Release
• Neutral Sentiment: Company guidance: Q1 2026 adjusted EPS of $1.120–1.180 (below the ~1.20 consensus) and FY 2026 adjusted EPS of $5.55–5.80 (around consensus). Guidance tempered near‑term expectations but keeps mid/longer‑term growth intact. Press Release
• Negative Sentiment: Revenue missed Street estimates (~$11.46–11.5B reported vs. ~$11.8–11.9B expected); the Nutrition business declined sharply (near‑9% year‑over‑year) and Diagnostics weakened (lower COVID testing and volatility), which triggered the market sell‑off. Reuters Blockonomi
• Negative Sentiment: Unusual bearish positioning: intraday put option volume spiked sharply, indicating heavy hedging or speculative bearish bets that can amplify downward price moves. (Reported market activity)
• Negative Sentiment: Regulatory/legal overhang: documents show India regulators are scrutinizing supply of a codeine‑based cough syrup tied to abuse investigations, introducing potential reputational and compliance risk. Reuters

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.